Skip to main content
Top
Published in: Clinical Rheumatology 3/2015

01-03-2015 | Original Article

Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus

Authors: Hejun Li, Shunping Lin, Shangchih Yang, Ling Chen, Xiangxiong Zheng

Published in: Clinical Rheumatology | Issue 3/2015

Login to get access

Abstract

In 2009, hypocomplementemia involving C3, C4, and total hemolytic complement (CH50) was proposed as an immunologic criterion to enhance the sensitivity of systemic lupus erythematosus (SLE) classification criteria. This study evaluated the diagnostic value of low serum complement C3 and C4 levels in Chinese patients with SLE. In total, 2452 patients were enrolled in this study (158 with SLE and 2294 with other diseases). Receiver operating characteristic analysis showed that the optimal C3 and C4 cut-off levels for a diagnosis of SLE were 0.785 g/L (sensitivity, 77.9 %; specificity, 81.5 %) and 0.145 g/L (sensitivity, 80.1 %; specificity, 83.2 %), respectively. The prevalence of a low C3 or C4 level alone was similar between patients with SLE and those with other diseases, while the prevalence of simultaneously low C3 and C4 levels was higher in patients with SLE (73.42 %). Antinuclear antibody had a high sensitivity (96.64 %) and low negative likelihood ratio (0.04). Hypocomplementemia with positive antinuclear antibody had a high positive likelihood ratio. Inclusion of hypocomplementemia as a classification criterion for SLE resulted in a 16.18 % increase in the number of patients assigned to the SLE group (from 136 to 158 patients). Hypocomplementemia was highly prevalent in patients with hematological disease (41.94 %). These results suggest that hypocomplementemia has important diagnostic value for SLE by improving the sensitivity of the diagnosis of SLE. C3 and C4 should be tested simultaneously because a low C3 or C4 level alone is not a suitable immunological criterion.
Literature
1.
go back to reference Gu YY (2012) Systemic lupus erythematosus. In: Wang JY, Liao EY, Huang CX, Hua Q (eds) Internal medicine, 2nd edn. People’s Medical Publishing House, Beijing, pp 1115–1123 Gu YY (2012) Systemic lupus erythematosus. In: Wang JY, Liao EY, Huang CX, Hua Q (eds) Internal medicine, 2nd edn. People’s Medical Publishing House, Beijing, pp 1115–1123
3.
go back to reference Petri M, Systemic Lupus International Collaborating Clinic (SLICC) (2009) SLICC revision of the ACR classification criteria for SLE [abstract]. Arthritis Rheum 60:895 Petri M, Systemic Lupus International Collaborating Clinic (SLICC) (2009) SLICC revision of the ACR classification criteria for SLE [abstract]. Arthritis Rheum 60:895
4.
go back to reference Li J, An L, Zhang Z (2014) Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Clin Exp Rheumatol 32:48–53PubMed Li J, An L, Zhang Z (2014) Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Clin Exp Rheumatol 32:48–53PubMed
5.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfeld NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfeld NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
6.
go back to reference Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed
7.
go back to reference Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedCentralPubMed Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedCentralPubMed
8.
go back to reference Julkunen H, Ekblom-Kullberg S, Miettinen A (2012) Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int 32:2445–2451CrossRefPubMed Julkunen H, Ekblom-Kullberg S, Miettinen A (2012) Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int 32:2445–2451CrossRefPubMed
9.
go back to reference Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B (2013) Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol 32(11):1619–1626CrossRefPubMed Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B (2013) Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol 32(11):1619–1626CrossRefPubMed
10.
go back to reference Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366CrossRefPubMedCentralPubMed Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366CrossRefPubMedCentralPubMed
11.
go back to reference Clowse ME, Magder LS, Petri M (2011) The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 38:1012–1016CrossRefPubMed Clowse ME, Magder LS, Petri M (2011) The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 38:1012–1016CrossRefPubMed
12.
go back to reference Kiani AN, Vogel-Claussen J, Magder LS, Petri M (2010) Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 37:579–584CrossRefPubMed Kiani AN, Vogel-Claussen J, Magder LS, Petri M (2010) Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 37:579–584CrossRefPubMed
13.
go back to reference Li J, An L, Zhang Z (2014) Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Clin Exp Rheumatol Exp Rheumatol 32(1):48–53 Li J, An L, Zhang Z (2014) Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Clin Exp Rheumatol Exp Rheumatol 32(1):48–53
14.
go back to reference Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA et al (2012) Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 64(12):4040–4047CrossRefPubMed Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA et al (2012) Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 64(12):4040–4047CrossRefPubMed
15.
go back to reference Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD, The Lupus Nephritis Collaborative Study Group (1991) Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. Am J Kidney Dis 18:678–685CrossRefPubMed Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD, The Lupus Nephritis Collaborative Study Group (1991) Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. Am J Kidney Dis 18:678–685CrossRefPubMed
16.
go back to reference Borba EF, Araujo DB, Bonfá E, Shinjo SK (2013) Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus 22:744–749CrossRefPubMed Borba EF, Araujo DB, Bonfá E, Shinjo SK (2013) Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus 22:744–749CrossRefPubMed
17.
go back to reference Ekwom PE (2013) Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital. Clin Rheumatol 32:1215–1217CrossRefPubMed Ekwom PE (2013) Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital. Clin Rheumatol 32:1215–1217CrossRefPubMed
18.
go back to reference Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM et al (2012) Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 64:3677–3686CrossRefPubMedCentralPubMed Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM et al (2012) Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 64:3677–3686CrossRefPubMedCentralPubMed
19.
go back to reference Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611CrossRefPubMed Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611CrossRefPubMed
Metadata
Title
Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus
Authors
Hejun Li
Shunping Lin
Shangchih Yang
Ling Chen
Xiangxiong Zheng
Publication date
01-03-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2843-4

Other articles of this Issue 3/2015

Clinical Rheumatology 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine